anti-Apolipoprotein A (APOA) Antibodies

The protein encoded by APOA is a serine proteinase that inhibits the activity of tissue-type plasminogen activator I. Additionally we are shipping Apolipoprotein A Kits (14) and Apolipoprotein A Proteins (4) and many more products for this protein.

list all antibodies Gene Name GeneID
APOA 4018
APOA  
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

Top anti-Apolipoprotein A Antibodies at antibodies-online.com

Showing 10 out of 47 products:

Catalog No. Reactivity Host Conjugate Application Images Quantity Supplier Delivery Price Details
Human Rabbit Un-conjugated WB WB Suggested Anti-LPA Antibody Titration: 0.2-1 ug/mlELISA Titer: 1:312500Positive Control: Jurkat cell lysate WB Suggested Anti-LPA  Antibody Titration: 0.2-1 µg/mL ELISA Titer: 1:.12500  Positive Control: Jurkat cell lysate 100 μL Log in to see 2 to 3 Days
$289.00
Details
Human Rabbit Un-conjugated WB WB Suggested Anti-LPA Antibody Titration: 0.2-1 ug/mlELISA Titer: 1:312500Positive Control: Jurkat cell lysate WB Suggested Anti-LPA  Antibody Titration: 0.2-1 µg/mL ELISA Titer: 1:.12500  Positive Control: Jurkat cell lysate 100 μL Log in to see 2 to 3 Days
$289.00
Details
Human Mouse Un-conjugated ICC, IHC, ELISA, WB Figure 1: Red: Control Antigen (100 ng), Purple: Antigen (10ng), Green: Antigen (50 ng), Blue: Antigen (100 ng) Figure 2: Immunofluorescence analysis of HepG2 cells using LPA mouse mAb (green) . Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin. 0.1 mg Log in to see 2 to 3 Days
$430.10
Details
Human Mouse Un-conjugated IHC, ELISA, WB Figure 1: Immunohistochemical analysis of paraffin-embedded human Liver tissues using LPA mouse mAb Figure 2: Western blot analysis using LPA mouse mAb against truncated LPA-His recombinant protein (1) and truncated Trx-LPA (aa4330-4521) recombinant protein (2) . 100 μL Log in to see 2 to 3 Days
$393.80
Details
Human Mouse Un-conjugated EIA, IHC (p), WB 50 μL Log in to see 6 to 8 Days
$500.50
Details
Human Goat Un-conjugated EIA, IHC (p) Human Liver (formalin-fixed, paraffin-embedded) stained with LPAfollowed by biotinylated anti-goat IgG secondary antibody, alkaline phosphatase-streptavidin and chromogen. 50 μg Log in to see 6 to 8 Days
$500.50
Details
Human Mouse Un-conjugated IHC, ELISA, WB   0.1 mL Log in to see 4 to 6 Days
$440.00
Details
Mammalian Sheep Un-conjugated EIA, WB   1 mg Log in to see 6 to 8 Days
$665.50
Details
Human Sheep Un-conjugated ELISA, WB   1 mg Log in to see 3 to 4 Days
$580.80
Details
Human Goat Un-conjugated ID   0.5 mL Log in to see 6 to 8 Days
$401.50
Details

APOA Antibodies by Reactivity, Application, Clonality and Conjugate

Attributes Applications Host Clonality Conjugate
Human , , , ,
, , ,
,
, ,
Mammalian


Top referenced anti-Apolipoprotein A Antibodies

  1. Human Monoclonal APOA Primary Antibody for IHC, ELISA - ABIN969261 : Ranga, Kalra, Tandon, Gambhir, Mehrotra: Effect of aspirin on lipoprotein(a) in patients with ischemic stroke. in Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2007 (PubMed)
    Show all 2 references for 969261

  2. Human Monoclonal APOA Primary Antibody for IHC, ELISA - ABIN966490 : : USA: bringing reality to the great American tobacco show. in Tobacco control 2007 (PubMed)
    Show all 2 references for 966490

  3. Human Monoclonal APOA Primary Antibody for ICC, IHC - ABIN969533 : Nicholls, Tang, Scoffone, Brennan, Hartiala, Allayee, Hazen: Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. in Journal of lipid research 2010 (PubMed)
    Show all 2 references for 969533

More Antibodies against Apolipoprotein A Interaction Partners

Human Apolipoprotein A (APOA) interaction partners

  1. Treatment of mildly hypercholesterolemic subjects with CETP (show CETP Antibodies) inhibitor anacetrapib reduces Lp(a) levels by decreasing its production.

  2. Structure, function, and genetics of Lp(a) with emphasis on the molecular and population genetics of the Lp(a)/LPA trait, as well as aspects of genetic epidemiology. [review]

  3. Due to new therapies that lower Lp(a) levels, there is renewed interest and still rising research activity in Lp(a). Despite all these activities, numerous gaps exist in our knowledge, especially as far as the function and metabolism of this fascinating Lp are concerned.

  4. This discovery has sparked intense interest in Lp(a) as a modifiable cause for aortic valve disease. Herein, we will review the mounting epidemiological and genetic findings in support of Lp(a)-mediated valve disease, discuss potential mechanisms underlying this observation, and outline the steps to translate this discovery to a much needed novel preventive and/or therapeutic strategy for aortic valve disease.

  5. Levels of lipoprotein (a) [Lp(a)], a complex between an LDL-like lipid moiety containing one copy of apoB (show APOB Antibodies), and apo(a), a plasminogen (show PLG Antibodies)-derived carbohydrate-rich hydrophilic protein, are primarily genetically rIncreasing evidence suggests that age, sex, and hormonal impact may have a modest modulatory influence on Lp(a) levels. Among clinical conditions, Lp(a) levels are reported to be affected by kidney and liver diseases.

  6. these studies support that reductions in Lp(a) with PCSK9 (show PCSK9 Antibodies) inhibition are partly due to increased LDLR (show LDLR Antibodies)-mediated uptake. In most situations, Lp(a) appears to compete poorly with LDL for LDLR (show LDLR Antibodies) binding and internalization, but when LDLR (show LDLR Antibodies) expression is increased with evolocumab, particularly in the setting of low circulating LDL, Lp(a) is reduced.

  7. Elevated Lp(a) level was an independent predictable risk factor for cardiovascular disease in type 2 diabetes.

  8. Recent genetic evidence documents elevated Lp(a) as a cause of myocardial infarction, atherosclerotic stenosis, and aortic valve stenosis

  9. APOE (show APOE Antibodies) genotypes strongly influence Lp(a) and apoB (show APOB Antibodies)-related lipoprotein levels.

  10. Lipoprotein apheresis has a lasting effect on prevention of cardiovascular events in patients with Lp(a)-hyperlipoproteinemia.

Apolipoprotein A (APOA) Antigen Profile

Protein Summary

The protein encoded by this gene is a serine proteinase that inhibits the activity of tissue-type plasminogen activator I. The encoded protein constitutes a substantial portion of lipoprotein(a) and is proteolytically cleaved, resulting in fragments that attach to atherosclerotic lesions and promote thrombogenesis. Elevated plasma levels of this protein are linked to atherosclerosis. Depending on the individual, the encoded protein contains 2-43 copies of kringle-type domains. The allele represented here contains 15 copies of the kringle-type repeats and corresponds to that found in the reference genome sequence.

Gene names and symbols associated with anti-Apolipoprotein A (APOA) Antibodies

  • lipoprotein, Lp(a) (LPA) antibody
  • AK38 antibody
  • Apo(a) antibody
  • APOA antibody
  • LP antibody
  • Lp(a) antibody

Protein level used designations for anti-Apolipoprotein A (APOA) Antibodies

antiangiogenic AK38 protein , apo(a) , apolipoprotein(a) , lp(a)

GENE ID SPECIES
4018 Homo sapiens
709528 Macaca mulatta
Selected quality suppliers for anti-Apolipoprotein A (APOA) Antibodies
Did you look for something else?